share_log

Private Companies Are Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥514m Last Week

Private Companies Are Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Biggest Owners and Were Rewarded After Market Cap Rose by CN¥514m Last Week

私人公司是福建萬臣生物科技集團有限公司(SZSE:300972)的最大股東,在市值上週上漲了51400萬元人民幣後得到了回報。
Simply Wall St ·  2024/08/30 08:09

Key Insights

關鍵見解

  • Fujian Wanchen Biotechnology Group's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public
  • A total of 3 investors have a majority stake in the company with 54% ownership
  • Insider ownership in Fujian Wanchen Biotechnology Group is 15%
  • 福建萬晨生物科技集團擁有大量私營公司所有權,這表明關鍵決策受廣大公衆股東的影響
  • 共有3位投資者持有該公司的多數股權,所有權爲54%
  • 福建萬晨生物科技集團的內部所有權爲15%

A look at the shareholders of Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private companies with 45% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

看看福建萬晨生物科技集團股份有限公司(SZSE: 300972)的股東可以告訴我們哪個集團最強大。而持有最大份額的集團是擁有45%所有權的私營公司。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

Clearly, private companies benefitted the most after the company's market cap rose by CN¥514m last week.

顯然,在上週該公司的市值上漲了51400萬元人民幣之後,私營公司受益最大。

In the chart below, we zoom in on the different ownership groups of Fujian Wanchen Biotechnology Group.

在下圖中,我們放大了福建萬晨生物科技集團的不同所有權組。

1724976541289
SZSE:300972 Ownership Breakdown August 30th 2024
SZSE: 300972 所有權明細 2024 年 8 月 30 日

What Does The Institutional Ownership Tell Us About Fujian Wanchen Biotechnology Group?

關於福建萬晨生物科技集團,機構所有權告訴我們什麼?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

機構在向自己的投資者報告時通常會根據基準來衡量自己,因此,一旦股票被納入主要指數,他們通常會對股票更加熱情。我們預計大多數公司都會有一些機構在冊,尤其是在它們正在成長的情況下。

Fujian Wanchen Biotechnology Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Fujian Wanchen Biotechnology Group's historic earnings and revenue below, but keep in mind there's always more to the story.

福建萬晨生物科技集團已經在股份登記處設立了機構。事實上,他們擁有該公司可觀的股份。這可能表明該公司在投資界具有一定程度的信譽。但是,最好謹慎行事,不要依賴機構投資者所謂的驗證。他們也是,有時候會弄錯。當多家機構擁有一隻股票時,總是存在處於 「擁擠交易」 的風險。當這樣的交易出錯時,多方可能會競相快速出售股票。對於沒有增長曆史的公司,這種風險更高。你可以在下面看到福建萬晨生物科技集團的歷史收益和收入,但請記住,故事總是有更多內容。

1724976542748
SZSE:300972 Earnings and Revenue Growth August 30th 2024
SZSE: 300972 收益和收入增長 2024 年 8 月 30 日

Hedge funds don't have many shares in Fujian Wanchen Biotechnology Group. Fujian Mimosa Agricultural Development Co., Ltd. is currently the largest shareholder, with 23% of shares outstanding. Zhangzhou Jinwanchen Investment Co., Ltd. is the second largest shareholder owning 17% of common stock, and Zening Wang holds about 14% of the company stock. Zening Wang, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.

對沖基金在福建萬晨生物科技集團的股份不多。福建含羞草農業發展有限公司目前是最大股東,已發行股份23%。漳州金萬晨投資有限公司是第二大股東,擁有17%的普通股,王澤寧持有公司約14%的股份。第三大股東王澤寧也恰好擁有董事會成員的頭銜。

To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

爲了使我們的研究更有趣,我們發現前三名股東擁有公司的多數股權,這意味着他們足夠強大,足以影響公司的決策。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

研究機構所有權是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒也可以達到同樣的目的。儘管有一些分析師的報道,但該公司的報道可能並不廣泛。因此,在未來它可能會引起更多關注。

Insider Ownership Of Fujian Wanchen Biotechnology Group

福建萬晨生物科技集團的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

不同國家對內部人士的定義可能略有不同,但董事會成員始終算在內。管理層最終對董事會負責。但是,經理成爲執行委員會成員的情況並不少見,尤其是當他們是創始人或首席執行官時。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲這可能表明董事會與其他股東關係良好。但是,在某些情況下,過多的權力集中在該群體中。

It seems insiders own a significant proportion of Fujian Wanchen Biotechnology Group Co., Ltd.. Insiders own CN¥828m worth of shares in the CN¥5.6b company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

內部人士似乎擁有福建萬晨生物科技集團有限公司的很大一部分股份。內部人士擁有這家56元人民幣公司價值82800萬元人民幣的股份。很高興看到內部人士對這項業務進行如此投資。可能值得檢查一下這些內部人士最近是否在買入。

General Public Ownership

一般公有制

With a 25% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Fujian Wanchen Biotechnology Group. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

福建萬晨生物科技集團擁有 25% 的所有權,主要是個人投資者,在一定程度上對福建萬晨生物科技集團有影響力。儘管這種所有權規模可能不足以影響對他們有利的政策決定,但它們仍然可以對公司政策產生集體影響。

Private Company Ownership

私人公司所有權

Our data indicates that Private Companies hold 45%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們的數據表明,私人公司持有該公司45%的股份。私營公司可能是關聯方。有時,內部人士通過持有私人公司而非以個人身份持有上市公司的權益。儘管很難得出任何廣泛的結論,但值得注意的是,這是一個有待進一步研究的領域。

Next Steps:

後續步驟:

It's always worth thinking about the different groups who own shares in a company. But to understand Fujian Wanchen Biotechnology Group better, we need to consider many other factors. Take risks for example - Fujian Wanchen Biotechnology Group has 2 warning signs we think you should be aware of.

擁有公司股份的不同群體總是值得考慮的。但是,要更好地了解福建萬晨生物科技集團,我們需要考慮許多其他因素。以風險爲例-福建萬晨生物科技集團有兩個警示信號,我們認爲你應該注意。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接聯繫我們。或者,也可以發送電子郵件至編輯團隊 (at) simplywallst.com。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論